T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a Business, Stakeholder, Technology and Pipeline Analysis

Date: June 1, 2019
Pages: 463
Price:
US$ 2,700.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T48657D0B28EN
Leaflet:

Download PDF Leaflet

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a Business, Stakeholder, Technology and Pipeline Analysis
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

Immunotherapy of cancer with T-cells oder NK cells is an area of great interest for the biopharmaceutical industry. Chimeric antigen receptor (CAR) engineered T-cell or NK cells represent one treatment modality under clinical evaluation, but the majority of Big Pharma prefers the engagement of T-cells or NK cells by recombinant monoclonal antibodies as off-the-shelf products. As only a few major pharmaceutical companies have clinically validated in-house bispecific antibody technology, partnering with technology providing companies is of great importance.

Within three years, the number of clinical stage T-cell and NK cell engagers has more than doubled and further product candidates will enter clinical evaluation in the near future.

This report will show you that there are plenty of opportunities for players in the field, including major pharmas, technology providers and investors.

This report will inform you about Big Pharma’s
  • In-house technologies and product candidates;
  • Technology and target in-licensing preferences;
  • Preferred product profile (half-life, safety features, effector cell type, and target type);
  • Economic deal terms.
38 technology companies with T-cell and NK cell engaging bispecific antibody technologies are analyzed regarding their
  • In house established technologies to redirect T-cells and NK cells or engage cotimulatory molecules;
  • Emerging technologies to generate bispecifics with longer half-life, greater safety, higher efficacy and to target intracellular targets via peptide MHC complexes;
  • In-house product candidates in development (technology used, construct, target, indication, R&D phase).
The profiles of 58 clinical stage and 25 non-clinical development stage T-cell and NK cell engaging bispecific antibodies form the basis of
  • Competitor analysis for a given target
  • Description of popular targets and bispecific antibody technologies
  • Discussion of product candidates from emerging next generation technologies
  • Learnin from clinical experience in hematologic and solid tumor indications.
So far, the attrition rate of T-cell and NK cell engaging antibodies is relatively low (12%). This report identified the terminated bispecific T-cell engager projects and the reasons for discontinuation.

This report also analyzes the financial „maturity“ of technology companies and their specific sources of funding. Overall, raising money for bispecific T-cell and NK cell engagers is no fundamental problem

What will you find in the report?
  • Profiles of 56 companies active in the field;
  • Comprehensive description and analysis of 38 established or emerging T-cell or NK-cell engaging antibody technologies;
  • Profiles of one approved, 89 T-cell or NK-cell engaging bispecific antibodies in all phases of development, and analysis of eight discontinued bispecific T-cell engagers;
  • Technology selection and preferences of major pharma;
  • Key characteristics of technologies with clinical stage drug candidates;
  • Emerging alternative bi- and trispecific formats;
  • Target selection and competition of drug candidates;
  • Competitive evaluation of clinical experience with bispecific T-cell and NK cell engagers;
  • Economic terms of collaboration and licensing deals;
  • Sources of financing.
Who will benefit from the report?
  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy analysts and managers;
  • Chief Technology Officer;
  • R&D Management in Oncology;
  • R&D Portfolio, Technology and Strategy Management;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.
1 EXECUTIVE SUMMARY

2 INTRODUCTION

3 STAKEHOLDER AND TECHNOLOGY ANALYSIS OF MAJOR PHARMACEUTICAL COMPANIES

4 STAKEHOLDER AND TECHNOLOGY ANALYSIS OF TECHNOLOGY COMPANIES

4.1 Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
4.2 Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
4.3 Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
4.4 Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies

5 PIPELINE ANALYSIS OF T-CELL AND NK CELL ENGAGING BISPECIFIC ANTIBODIES

5.1 Tumor Targeting & Effector Cell Engagement
5.2 Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies
5.3 Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies
5.4 Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies
5.5 Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies
5.6 Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies
5.7 Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies
5.8 Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies
5.9 Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies

6 SOURCES OF FINANCING AND PARTNERING DEALS OF TECHNOLOGY COMPANIES

7. COMPANY PROFILES

7.1. Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies
7.2 Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.3 Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.4 Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
7.5 7.5 Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies

8 TECHNOLOGY PROFILES

8.1 Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
8.2 Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
8.3 Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie
8.4 Novel „Special“ T-Cell and NK Cell Engaging Bispecific Antibody Technologies

9 DRUG AND DRUG CANDIDATE PROFILES

  9.1.1 A-319
  9.1.2 A-337
  9.1.3 ABBV-428
  9.1.4 ABP-100
  9.1.5 ABP-110
  9.1.6 ABP-150
  9.1.7 AFM13
  9.1.8 AFM14
  9.1.9 AFM26
  9.1.10 ALG.APV-527
  9.1.11 AMG
  9.1.12 AMG
  9.1.13 AMG
  9.1.14 AMG
  9.1.15 AMG
  9.1.16 AMG
  9.1.17 AMG
  9.1.18 AMG
  9.1.19 AMG
  9.1.20 AMG
  9.1.21 AMG
  9.1.22 AMV564
  9.1.23 Anti-FLT3
  9.1.24 Anti-ROR1
  9.1.25 APVO436
  9.1.26 ARB-201
  9.1.27 Blincyto
  9.1.28 BMS-986277
  9.1.29 CB307
  9.1.30 CC-93269
  9.1.31 ERY974
  9.1.32 GBR1302
  9.1.33 GBR1342
  9.1.34 GBR1372
  9.1.35 GEM3PSCA
  9.1.36 GEM333
  9.1.37 GEN3013
  9.1.38 HPN217
  9.1.39 HPN328
  9.1.40 HPN424
  9.1.41 HPN536
  9.1.42 IGM2323
  9.1.43 IMC-C103C
  9.1.44 IMC-F106C
  9.1.45 IMCgp100
  9.1.46 IMCnyeso
  9.1.47 IPH61
  9.1.48 JNJ-63709178
  9.1.49 JNJ-6389808
  9.1.50 JNJ-64007957
  9.1.51 JNJ-64407564
  9.1.52 JNJ-67571244
  9.1.53 M701
  9.1.54 M802
  9.1.55 MCLA-117
  9.1.56 MCLA-145
  9.1.57 MG1122
  9.1.58 MGD006
  9.1.59 MGD007
  9.1.60 MGD009
  9.1.61 MGD014
  9.1.62 MO0310
  9.1.63 ND021
  9.1.64 NG-641
  9.1.65 OXS-1615
  9.1.66 OXS-3550
  9.1.67 OXS-C3550
  9.1.68 PF-06671008
  9.1.69 PF-06863135
  9.1.70 PRS-342
  9.1.71 REGN1979
  9.1.72 REGN4018
  9.1.73 REGN5458
  9.1.74 RG6026
  9.1.75 RG6160
  9.1.76 RG6194
  9.1.77 RG7802
  9.1.78 RG7827
  9.1.79 RG7828
  9.1.80 SAR440234
  9.1.81 TNB-383B
  9.1.82 TNB-486
  9.1.83 TNB-585
  9.1.84 TSA(1)-CD28 & TSA(2)-CD28
  9.1.85 VB-600
  9.1.86 XmAb13676
  9.1.87 XmAb14045
  9.1.88 XmAb18087
  9.1.89 XmAb23104
  9.1.90 Y111
10 References

TABLES IN THE TEXT

Table 1 Big Pharma’s In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 2 Big Pharma’s Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 3 Big Pharma’s Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 4 Big Pharma’s Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 5 Economic Terms of Big Pharma’s Collaboration & Licensing Agreements for T-Cell & NK Cell Engaging Bispecific Antibody Technologies
Table 6 Main Characteristics of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies
Table 7 Safety and Effector Cell Features of Big Pharma’s T-cell Engaging Bispecific Antibody Technologies
Table 8 Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma’s Proprietary T-cell and NK Cell Engaging Bispecific Antibodies
Table 9 Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
Table 10 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 11 Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 12 Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 13 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 14 Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 15 Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 16 Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies
Table 17 Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 18 Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 19 Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies
Table 20 Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies
Table 21 Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies
Table 22 Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
Table 23 Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
Table 24 Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies
Table 25 Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 26 Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 27 Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 28 Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 29 Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
Table 30 Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies
Table 31 Amgen’s Bispecific T-Cell Engager Pipeline
Table 32 Celgene’s Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies
Table 33 Janssen’s Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 34 Pfizer’s T-cell Engaging Bispecific Antibody Pipeline
Table 35 Roche’s Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies
Table 36 Sanofi’s Bispecific T-Cell and NK Cell Engager Pipeline
Table 37 Abpro’s Pipeline of T-Cell Engaging TetraBi Antibodies
Table 38 Merus‘ Biclonics Development Pipeline
Table 39 Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline
Table 40 TeneoBio’s Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies
Table 41 YZY Biopharma‘s Pipeline of T-Cell Redirecting Bispecific Antibodies
Table 42 Partnering Terms for Zymeworks‘ Azymetric Technology
Table 43 Pipeline of ADAPTIR Molecules from Aptevo Therapeutics
Table 44 MacroGenics‘ Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies
Table 45 Xencor’s Bispecific T-Cell Engaging Antibody Pipeline
Table 46 Generon’s Pipeline of Bispecific ITab Antibodies
Table 47 Harpoon Therapeutics‘ TriTAC Pipeline
Table 48 Affimed Therapeutics‘ T-Cell and NK-Cell Engaging Antibody Pipeline
Table 49 GT Biopharma‘ Pipeline of Tri- and Tetra-Specific NK Cell Engagers
Table 50 Goals and Terms of Immunocore’s Industry Partnering Deals for ImmTAC Technology
Table 51 Immuncore’s Wholly Owned and Partnered Development Pipeline of ImmTACs
Table 52 Blincyto Global Sales
Table 53 Clinical Studies with IMCgp100

COMPANIES MENTIONED IN THE REPORT

AbbVie
Abpro
Adimab
Affimed Therapeutics
Alligator Bioscience
Amgen
Amphivena Therapeutics
Aptevo Therapeutics
Arbele
Astellas Pharma
AstraZeneca
BenHealth Biopharmaceuticals
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Crescendo Biologics
CytomX Therapeutics
Dragonfly Theraputics
Eli Lilly
GEMoaB Monoclonals
Generon
Genmab
GlaxoSmithKline
Glenmark Pharmaceuticals
GT Biopharma
Harpoon Therapeutics
IGM Biosciences
Immatics Biotechnologies
Immunocore
Innate Pharma
Inovio Pharmaceuticals
Janssen
Lava Therapeutics
MacroGenics
Maverick Therapeutics
Merck & Co.
Merus
Mogam Institute for Biomedical Research (MIBR)
Molecular Partners
NJCTTQ
Novartis
Numab
Pfizer
Pieris Pharmaceuticals
PsiOxus Therapeutics
Regeneron Pharmaceuticals
Revitope Oncology
Roche
Sanofi
Servier
Takeda Pharmaceutical Co.
TeneoBio
VBL Therapeutics
Xencor
YZY Biopharma
Zymeworks
Skip to top


Ask Your Question

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a Business, Stakeholder, Technology and Pipeline Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: